Investigational therapyJohnson & Johnson

JNJ-95475939

JNJ-95475939 (JNJ-5939) is an investigational Johnson & Johnson candidate evaluated in the Phase 2b DUPLEX-AD study in atopic dermatitis.

Also known as: JNJ-5939, JNJ-95475939

Forecast a trial in the ArenaBrowse all benchmarks
1
Trials tracked
0
Resolved
1
Indications
0
Targets

JNJ-95475939 forecasting benchmarks

1 benchmark
OpenPhase 2b

DUPLEX-AD (JNJ-95475939 / JNJ-5939) atopic dermatitis

JNJ-95475939 · Atopic dermatitis

Dec 26, 2025Clinical Trials

Indications studied

Atopic dermatitis· AD

Developed by

Johnson & Johnson· JNJ

About JNJ-95475939

What is JNJ-95475939?

JNJ-95475939 (JNJ-5939) is an investigational Johnson & Johnson candidate evaluated in the Phase 2b DUPLEX-AD study in atopic dermatitis. It is a investigational therapy developed by Johnson & Johnson.

What does JNJ-95475939 target?

JNJ-95475939's mechanism is summarized above; see the linked trial readouts for details.

How well do AI models predict JNJ-95475939 trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.

Keep exploring

All benchmarksDiseasesCompaniesTargets & genes